Caffeine, CYP1A2 Genotype, and Endurance Performance in Athletes
Guest N, Corey P, Vescovi J, El-Sohemy A
Medicine and science in sports and exercise · 140 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- Canadian Institutes of Health Research
- Gobierno
- CIHR
Según 2 financiadores declarados.
Publicación
- Publicado
- 2018-03-06 · Med Sci Sports Exerc · vol. 50 · número 8 · págs. 1570–1578
- Editorial
- Lippincott Williams & Wilkins
- Citado
- 231 citas · más que el 100% de estudios similares · 15.7× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 40 trabajos
- Acceso
- De pago
- Áreas de investigación
- Coffee research and impacts · Muscle metabolism and nutrition · Exercise and Physiological Responses
- Palabras clave
- Caffeine, CYP1A2, Cycling, Time trial, Placebo, Genotype, Internal medicine, Athletes, Saliva, Animal science, Endocrinology, Medicine, Chemistry, Biology, Metabolism, Heart rate, Physical therapy, Biochemistry, Gene, Cytochrome P450, Blood pressure
- MeSH
- humans, caffeine, cytochrome p-450 cyp1a2, exercise test, double-blind method, perception, heart rate, physical endurance, genotype, polymorphism, single nucleotide, adult, male, physical exertion, young adult
4 autores
- Nanci S. Guest🇨🇦University of Toronto
- Paul Corey🇨🇦University of Toronto; Public Health Ontario
- Jason D. Vescovi🇨🇦University of Toronto
- Ahmed El‐Sohemy🇨🇦University of Toronto
Resumen
El texto original del estudio, en el idioma en que se publicó.
Purpose
Many studies have examined the effect of caffeine on exercise performance, but findings have not always been consistent. The objective of this study was to determine whether variation in the CYP1A2 gene, which affects caffeine metabolism, modifies the ergogenic effects of caffeine in a 10-km cycling time trial.
Methods
Competitive male athletes (n = 101; age = 25 ± 4 yr) completed the time trial under three conditions: 0, 2, or 4 mg of caffeine per kilogram body mass, using a split-plot randomized, double-blinded, placebo-controlled design. DNA was isolated from saliva and genotyped for the -163A > C polymorphism in the CYP1A2 gene (rs762551).
Results
Overall, 4 mg·kg caffeine decreased cycling time by 3% (mean ± SEM) versus placebo (17.6 ± 0.1 vs 18.1 ± 0.1 min, P = 0.01). However, a significant (P <0.0001) caffeine-gene interaction was observed. Among those with the AA genotype, cycling time decreased by 4.8% at 2 mg·kg (17.0 ± 0.3 vs 17.8 ± 0.4 min, P = 0.0005) and by 6.8% at 4 mg·kg (16.6 ± 0.3 vs 17.8 ± 0.4 min, P < 0.0001). In those with the CC genotype, 4 mg·kg increased cycling time by 13.7% versus placebo (20.8 ± 0.8 vs 18.3 ± 0.5 min, P = 0.04). No effects were observed among those with the AC genotype.
Conclusion
Our findings show that both 2 and 4 mg·kg caffeine improve 10-km cycling time, but only in those with the AA genotype. Caffeine had no effect in those with the AC genotype and diminished performance at 4 mg·kg in those with the CC genotype. CYP1A2 genotype should be considered when deciding whether an athlete should use caffeine for enhancing endurance performance.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.